Inhibiting the FoxM1 protein may offer a new way to attack
prostate cancer, according to a study led by scientists at Cincinnati
published Aug. 2, 2013, in the Journal of
Biological Chemistry, shows that expression of the FoxM1 protein is
essential for prostate cancer to develop in mouse models. The study also shows
that depleting FoxM1 in prostate epithelial cells inhibits tumor cell
proliferation and metastasis.
“It is possible that FoxM1 is important for both cancer
initiation and cancer progression,” says Tanya Kalin, MD, PhD, a physician-scientist in the Division of Pulmonary Biology and senior author of the study. “Our findings provide the foundation for the
development of new therapeutic approaches based on inhibition of FoxM1.”
FoxM1 is known to be involved in most solid tumor cancers.
Kalin’s lab published a study in 2006 showing that increased levels of FoxM1
were associated with the development and progression of prostate cancer in
mice. Although the current study focuses primarily on prostate cancer, the
findings also may help researchers better understand other pediatric diseases.